Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal and cosmetic products, including plasters, bandages, herbal cosmetics, and sanitary-hygiene products; concentrates for hemodialysis; and prescription medicines, and OTC and veterinary medical products. In addition, the company distributes pharmaceuticals, medical supplies, sanitary materials, vitamins, food supplements, and cosmetics; and provides contract manufacturing services; packaging services; and product development services. Further, it is involved in trading of pharmaceuticals; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; purchases, grows, produces, and trades in herbs and medicinal plant; and provision of public opinion research services. Additionally, the company engages in the offline and online retail trade of medicinal products and medical equipment; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.
Metrics to compare | BGSFA | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipBGSFAPeersSector | |
---|---|---|---|---|
P/E Ratio | 13.8x | 15.7x | −0.5x | |
PEG Ratio | −0.57 | −0.01 | 0.00 | |
Price/Book | 1.4x | 2.7x | 2.6x | |
Price / LTM Sales | 0.5x | 2.1x | 3.3x | |
Upside (Analyst Target) | - | 34.0% | 43.5% | |
Fair Value Upside | Unlock | 12.0% | 6.3% | Unlock |